Neither produces the magnitude of weight loss seen with incretin peptides
How This Works This blend combines three complementary peptides with distinct mechanisms: AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism [1] [7]
Without controlled human exposure data, there is no validated human dose, treatment duration, monitoring programme, contraindication list or evidence-based interaction profile
"Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health." Journal of Endocrinology and Metabolism 4.3 (2014): 64-77
Understanding your body's stress response can inform lifestyle modifications and therapeutic interventions to optimize adrenal function
Product Attributes CAS # : 221231-10-3 Molecular Formula : C78H123N23O23S2 Sequence (AA) : YLRIVQCRSVEGSCGF (with disulfide bond between Cys-7 and Cys-14) Molecular Weight : 1815.1 g/mol PubChem CID : 71300630 Half-Life : ~4-6 hours Synonyms : Anti-Obesity Drug 9604, hGH Fragment 176-191, Lipolytic hGH Fragment, Tyr-hGH (177-191), Tyr-somatostatin Type : Synthetic research peptide (growth hormone fragment) Research Focus : Weight Loss & Metabolic Regulation Scientific References Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Animal The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Animal Safety and tolerability of the hexadecapeptide AOD9604 in humans Human RCT Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health Human RCT | Observational | Animal | In vitro Obesity pharmacotherapy: current perspectives and future directions Human RCT Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism Animal | In vitro Obesity drugs in clinical development Human RCT Recent advances in the pathophysiology and pharmacological treatment of obesity Human RCT | Observational Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors Observational Peptides: AOD-9604 & BPC-157 Human RCT | Animal | In vitro Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator
